Trial
NCT01537861
Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma
Early Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Washington University School of Medicine
Collaborators
—
Condition
Multiple Myeloma
Intervention
Filgrastim
Why stopped
Unexpected toxicity (2 early deaths)
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-01-26